drugset
drugset / Trial / NCT07089121

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

NCT07089121 ↗

Phase 1/2 Recruiting 50 enrolled Cartesian Therapeutics
Non-randomizedSequentialOpen-labelTreatment

Summary

Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis

Timeline

Start
2026-01-14
Primary completion
2027-12
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Descartes-08 Cell therapy — Other

Indications

anti-neutrophil cytoplasmic antibody-associated vasculitis juvenile dermatomyositis juvenile myasthenia gravis pediatric systemic lupus erythematosus